{"tool_name":"idh-wild-type","contents":["biotools","bioschemas"],"fetched_metadata":{"biotools":{"id":"IDH-wild-type","home":"https://gcioffi.shinyapps.io/Nomogram_For_IDH_Wildtype_GBM_H_Gittleman/","summary":"An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.\n\nBackground:In 2016, the World Health Organization reclassified the definition of glioblastoma (GBM), dividing these tumors into isocitrate dehydrogenase (IDH)-wild-type and IDH-mutant GBM, where the vast majority of GBMs are IDH-wild-type. Nomograms are useful tools for individualized estimation of survival. This study aimed to develop and independently validate a nomogram for IDH-wild-type patients with newly diagnosed GBM.","addition_date":"2020-01-09T18:20:06Z","last_update_date":"2020-12-14T08:28:15Z","tool_type":["Web application"]},"bioschemas":{"name":"IDH-wild-type","home":"https://bio.tools/IDH-wild-type","summary":"An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.\n\nBackground:In 2016, the World Health Organization reclassified the definition of glioblastoma (GBM), dividing these tumors into isocitrate dehydrogenase (IDH)-wild-type and IDH-mutant GBM, where the vast majority of GBMs are IDH-wild-type. Nomograms are useful tools for individualized estimation of survival. This study aimed to develop and independently validate a nomogram for IDH-wild-type patients with newly diagnosed GBM.","tool_type":"sc:SoftwareApplication"}}}